Myeloproliferative disease : subject feeds
HOXA9 has the hallmarks of a biological switch with implications in blood cancers
Allogeneic hematopoietic cell transplantation in patients with juvenile myelomonocytic leukemia in Korea: a report of the Korean Pediatric Hematology-Oncology Group
Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm
Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms—a nationwide population-based study of 342 pregnancies in Sweden
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
A CRISPR/Cas9 engineered MplS504N mouse model recapitulates human myelofibrosis
Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis
A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy
Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms
In utero origin of myelofibrosis presenting in adult monozygotic twins
GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes
The role of JAK inhibitors in hematopoietic cell transplantation
Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms
Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP
Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort
Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases
Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
Feed Fetched by RSS Dog.